ePrints

‘ACOPP’ chemotherapy for older and less fit patients with Hodgkin lymphoma—A multicentre, retrospective study

Lookup NU author(s): Dr Wendy Osborne

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2023 British Society for Haematology and John Wiley & Sons Ltd.Management of classical Hodgkin lymphoma in older patients is challenging due to poor tolerance of the chemotherapy regimens used in younger patients. We modified the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone), whereby bleomycin and etoposide were removed and cyclophosphamide dose was reduced, for older patients with co-morbidities. Here we present data from the first 41 patients treated with ‘ACOPP’ across 3 centres, demonstrating that it can be delivered, with a favourable toxicity profile (TRM 2%) and promising efficacy (2-year PFS and OS, 73% (95% CI: 52–94) and 93% (95% CI: 80–100) respectively).

Publication metadata

Author(s): Wilson MR, Haynes E, Parsons K, Hopkins D, Robertson E, Ferguson G, Quinn D, Murray J, Osborne W, Leach M, McKay P

Publication type: Article

Publication status: Published

Journal: British Journal of Haematology

Year: 2023

Volume: 202

Issue: 4

Pages: 796-800

Online publication date: 25/06/2023

Acceptance date: 13/06/2023

ISSN (print): 0007-1048

ISSN (electronic): 1365-2141

Publisher: John Wiley and Sons Inc

URL: https://doi.org/10.1111/bjh.18947

DOI: 10.1111/bjh.18947

Altmetrics

Share